Lamotrigine vs Rufinamide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Lamotrigine

Marketed by GlaxoSmithKline

Approved in Epilepsysmall molecule
Weak signal

NCT01431976 · Phase 3 · completed

This was a small, single-arm, open-label study of 20 participants, with no randomization, blinding, or comparator. The primary clinical endpoint found 7 of 20 participants (35%) seizure free by hyperventilation-EEG at the end of maintenance, but there was no formal between-group comparison.

Reported efficacy

Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 (missed)

Result source: NCT00088452

Rufinamide

Marketed by Eisai and partners

Approved in Epilepsysmall molecule
Partial signal

NCT00334958 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011.

The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis.

Reported efficacy

Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96): Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). (met)

Result source: NCT00334958

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLamotrigineRufinamide
Seizure frequency, % change75.4% vs 32.1%+43.3 vs placebowk 19 · n 69NCT00104416—Not reported
50% responder rate—Not posted · NCT00007670—Not reported
Seizure freedom—Not posted · NCT00007670—Not reported

Seizure frequency, % change

Lamotrigine
75.4% vs 32.1%+43.3 vs placebowk 19 · n 69NCT00104416
Rufinamide
—Not reported

50% responder rate

Lamotrigine
—Not posted · NCT00007670
Rufinamide
—Not reported

Seizure freedom

Lamotrigine
—Not posted · NCT00007670
Rufinamide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lamotrigine: 4 of 4 rows · Rufinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLamotrigineRufinamide
Dropout rate
70%a
NCT01431976 · Phase 3 · monotherapy
show 16 more results
0%
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3
—
NCT02404168 · Phase 4 · registry result, not featured evidence
—
NCT01995825 · Phase 4 · registry result, not featured evidence
52.2%
NCT01431963 · Phase 3 · registry result, not featured evidence
—
NCT00516139 · Phase 3 · registry result, not featured evidence
20%
NCT00292461 · Phase 3 · registry result, not featured evidence
3.9%Adolescents: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
2%Adults: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
16.8%300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
30.1%250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
13.2%
NCT00104416 · Phase 3 · registry result, not featured evidence
0%
NCT00789113 · Phase 1/2 · registry result, not featured evidence
—
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
21%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
13.8%
NCT01146951 · Phase 3 · monotherapy
40%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
24.1%
NCT01151540 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
30%a
NCT01431976 · Phase 3 · monotherapy
show 16 more results
—
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3
—
NCT02404168 · Phase 4 · registry result, not featured evidence
—
NCT01995825 · Phase 4 · registry result, not featured evidence
26.9%
NCT01431963 · Phase 3 · registry result, not featured evidence
—
NCT00516139 · Phase 3 · registry result, not featured evidence
6.7%
NCT00292461 · Phase 3 · registry result, not featured evidence
3.9%Adolescents: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
2%Adults: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
8.8%250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
1.3%
NCT00104416 · Phase 3 · registry result, not featured evidence
—
NCT00789113 · Phase 1/2 · registry result, not featured evidence
—
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
15.3%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
13.8%
NCT01146951 · Phase 3 · monotherapy
12%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
7.4%
NCT01151540 · Phase 3 · registry result, not featured evidence
Serious AEs
0%a
NCT01431976 · Phase 3 · monotherapy
show 16 more results
1.3%
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3
0%
NCT02404168 · Phase 4 · registry result, not featured evidence
0%
NCT01995825 · Phase 4 · registry result, not featured evidence
12.3%
NCT01431963 · Phase 3 · registry result, not featured evidence
18.2%
NCT00516139 · Phase 3 · registry result, not featured evidence
3.3%
NCT00292461 · Phase 3 · registry result, not featured evidence
3.9%Adolescents: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
9.8%Adults: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
1.6%300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
2.7%300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
4.5%250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
1.4%
NCT00104416 · Phase 3 · registry result, not featured evidence
0%
NCT00789113 · Phase 1/2 · registry result, not featured evidence
0%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
3.4%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
3.4%
NCT01146951 · Phase 3 · monotherapy
40%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
16.7%
NCT01151540 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 35%
rash 30%
bronchitis 25%
NCT01431976 · Phase 3 · monotherapy
show 13 more results
fatigue 8.7%
headache 8.1%
hostility 6.7%
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3
dizziness 50%
headache 50%
NCT02404168 · Phase 4 · registry result, not featured evidence
headache 11.4%
dizziness 5.7%
blurred vision 2.9%
NCT01995825 · Phase 4 · registry result, not featured evidence
nasopharyngitis 23.1%
headache 21.5%
rash 12.3%
NCT01431963 · Phase 3 · registry result, not featured evidence
dizziness 25.6%
balance disorder 20.7%
fall 18.2%
NCT00516139 · Phase 3 · registry result, not featured evidence
diplopia 10%
dizziness 6.7%
insomnia 6.7%
NCT00292461 · Phase 3 · registry result, not featured evidence
upper respiratory tract inflammation 29.4%
nasopharyngitis 27.5%
diarrhoea 21.6%
NCT00395694 · Phase 3 · registry result, not featured evidence
dizziness 19.6%
nasopharyngitis 19.6%
contusion 15.7%
NCT00395694 · Phase 3 · registry result, not featured evidence
300 mg
headache 17.9%
dizziness 6%
nausea 3.3%
NCT00355082 · Phase 3 · registry result, not featured evidence
300 mg
headache 25.9%
dizziness 10.7%
nasalpharyngitis 6.3%
NCT00355082 · Phase 3 · registry result, not featured evidence
250 mg
headache 27.9%
rash 10.8%
dizziness 9%
NCT00355082 · Phase 3 · registry result, not featured evidence
headache 13.9% (placebo 16.2%)
vomiting 9.7% (placebo 4.1%)
nausea 6.9% (placebo 5.4%)
NCT00104416 · Phase 3 · registry result, not featured evidence
somnolence 80%
dizziness 66.7%
headache 60%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
b
dizziness 26.7% (placebo 8.3%)
headache 16.5% (placebo 12.8%)
fatigue 15.3% (placebo 10%)
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
nasopharyngitis 31% (placebo 30%)
status epilepticus 27.6% (placebo 16.7%)
decreased appetite 20.7% (placebo 6.7%)
NCT01146951 · Phase 3 · monotherapy
upper respiratory tract infection 28%
vomiting 28%
somnolence 20%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
nasopharyngitis 48.1%
status epilepticus 40.7%
somnolence 25.9%
NCT01151540 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 16 of these studies.
  2. bPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lamotrigine

Seizure-free 35% (n=20) @ 50wk
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT01431976 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
show 2 more results
100% (n=7) @ 4wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
100% (n=7) @ 8wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
Seizure-free 24.7% (n=89) @ 23wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT00355082 · Phase 3 · registry result, not featured evidence · converted to % from 22 participants as posted
show 2 more results
10.5% (n=76) @ 23wk*250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence · converted to % from 8 participants as posted
40% (n=20)*
NCT01431976 · Phase 3 · monotherapy · converted to % from 8 Participants as posted
Seizure-free 30% (n=20) @ 12wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
show 13 more results
25% (n=20) @ 36wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 5 Participants as posted
30% (n=20) @ 60wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
30% (n=20) @ 84wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
30% (n=20) @ 108wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
30% (n=20) @ 132wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
10% (n=20) @ 156wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 2 Participants as posted
25% (n=20) @ 24wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 5 Participants as posted
30% (n=20) @ 48wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
25% (n=20) @ 72wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 5 Participants as posted
30% (n=20) @ 96wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
25% (n=20) @ 120wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 5 Participants as posted
10% (n=20) @ 144wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 2 Participants as posted
5% (n=20) @ 168wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 1 Participants as posted
Seizure Days Per 0.1 months
absolute value · months
Maintenance
No placebo or comparator arm
FEP+EP+MP, n=20
NCT01431976 · Phase 3 · monotherapy · converted to months from 2.98 days as posted
Seizure Days Per 0 months
absolute value · months
Extension (open-label)
No placebo or comparator arm
NCT01431976 · Phase 3 · monotherapy · converted to months from 0.03 days as posted
Treatment Failure Free 29.5% (n=146) vs 58.2% (n=146) Valproic Acid @ 20wk
event count · % of participants
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 · converted to % from 43 Participants as posted
show 1 more result
21.2% (n=146) vs 43.8% (n=146) Valproic Acid @ 52wk*
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 · converted to % from 31 Participants as posted
Seizure Free 6 43.1% (n=65) @ 30wk
event count · % of participants
Maintenance
No placebo or comparator arm
All, n=65
NCT01431963 · Phase 3 · registry result, not featured evidence · converted to % from 28 participants as posted
Time to First Seizure 3.38 months @ 30wk
time to event · months
Maintenance
No placebo or comparator arm
All, n=52
NCT01431963 · Phase 3 · registry result, not featured evidence · converted to months from 103 days as posted
Partial Seizure Frequency 97.8% (n=55) @ 7wk
percent change · % of baseline
Maintenance
No placebo or comparator arm
Dose-Escalation Phase (Week 7), n=55
NCT00516139 · Phase 3 · registry result, not featured evidence
Partial Seizure Frequency 100% (n=55) @ 15wk
percent change · % of baseline
Maintenance
No placebo or comparator arm
Maintenance Phase (Week 15), n=43
NCT00516139 · Phase 3 · registry result, not featured evidence
Partial Seizure Frequency 90.4% (n=55)
percent change · % of baseline
Maintenance
No placebo or comparator arm
End Of Treatment (Week 30/33), n=55
NCT00516139 · Phase 3 · registry result, not featured evidence
Seizure-free 80.3% (n=66)
event count · % of participants
No placebo or comparator arm
Remained Seizure-Free
NCT00516139 · Phase 3 · registry result, not featured evidence · converted to % from 53 participants as posted

+ 15 further endpoints in the CSV export.

Rufinamide

Seizure Frequency 50 32.5% (n=160) vs 14.3% (n=175) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
Tonic-atonic Seizure 50% Reduction 25% (n=28) vs 6.7% (n=30) placebo @ 12wk
event count · % of participants
Yes (50% Reduction Achieved)
NCT01146951 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
Drop Seizure Frequency -39.3% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -40.6% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -46.8% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -47.6% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -36.05% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.7% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -48.9% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -50.6% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -52% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.35% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence

+ 5 further endpoints in the CSV export.

Lennox-Gastaut Syndrome

Shared mechanism: Voltage-gated sodium channel · full Lennox-Gastaut Syndrome pipeline

Lamotrigine

Marketed by GlaxoSmithKline

Approved in Lennox-Gastaut Syndromesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Rufinamide

Marketed by Eisai and partners

Approved in Lennox-Gastaut Syndromesmall molecule
Partial signal

NCT01146951 · Phase 3 · completed

Participants were randomized to quadruple-blind rufinamide or placebo, with 59 entering treatment and 58 included in the full analysis set. The primary clinical endpoint was met, with a statistically significant reduction in tonic-atonic seizure frequency, but the small sample limits the strength of the evidence.

Reported efficacy

Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) (Baseline (28 day observational period) and End of Treatment (28 day treatment period)): Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) (Baseline (28 day observational period) and End of Treatment (28 day treatment period)): Rufinamide (E2080) -24.2 Percent Change (range -93.5 to 27.2) | Placebo -3.25 Percent Change (range -81.6 to 151.9) (met)

Result source: NCT01146951

Results for Lennox-Gastaut Syndrome

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Lamotrigine: no structured comparison results are available for Lennox-Gastaut Syndrome.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Rufinamide

Tonic-atonic Seizure 50% Reduction 25% (n=28) vs 6.7% (n=30) placebo @ 12wk
event count · % of participants
Yes (50% Reduction Achieved)
NCT01146951 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
Drop Seizure Frequency -39.3% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -40.6% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -46.8% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -47.6% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -36.05% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.7% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -48.9% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -50.6% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -52% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.35% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence
Tonic-Atonic Seizure 50% Reduction 43.5% (n=46) @ 12wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
Week 12 50% Reduction - Yes
NCT01151540 · Phase 3 · registry result, not featured evidence

+ 4 further endpoints in the CSV export.

Available safety results

Rufinamide

Dropout rate
13.8%
NCT01146951 · Phase 3 · monotherapy
show 2 more results
40%
NCT01405053 · Phase 3 · registry result, not featured evidence · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
24.1%
NCT01151540 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
13.8%
NCT01146951 · Phase 3 · monotherapy
show 2 more results
12%
NCT01405053 · Phase 3 · registry result, not featured evidence · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
7.4%
NCT01151540 · Phase 3 · registry result, not featured evidence
Serious AEs
3.4%
NCT01146951 · Phase 3 · monotherapy
show 2 more results
40%
NCT01405053 · Phase 3 · registry result, not featured evidence · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
16.7%
NCT01151540 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
nasopharyngitis 31% (placebo 30%)
status epilepticus 27.6% (placebo 16.7%)
decreased appetite 20.7% (placebo 6.7%)
NCT01146951 · Phase 3 · monotherapy
show 2 more results
upper respiratory tract infection 28%
vomiting 28%
somnolence 20%
NCT01405053 · Phase 3 · registry result, not featured evidence · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
nasopharyngitis 48.1%
status epilepticus 40.7%
somnolence 25.9%
NCT01151540 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lamotrigine's landscape · Rufinamide's landscape